Antiplatelet therapies for the treatment of cardiovascular disease

被引：320

作者：

Michelson, Alan D. ^{[1
]}

机构：

[1] Childrens Hosp Boston, Ctr Platelet Res Studies, Boston, MA 02115 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2010年 / 9卷 / 02期

关键词：

PERCUTANEOUS CORONARY INTERVENTION; ACUTE MYOCARDIAL-INFARCTION; PLATELET-FUNCTION PROFILES; A(2) RECEPTOR ANTAGONIST; ASPIRIN-TREATED PATIENTS; OXIDE-RELEASING ASPIRIN; PROTON PUMP INHIBITORS; GLYCOPROTEIN IIB/IIIA; DOUBLE-BLIND; IN-VIVO;

D O I：

10.1038/nrd2957

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Antiplatelet therapy has been successful in reducing mortality and morbidity in acute myocardial infarction. Recent advances in understanding the molecular basis of the role of platelets in cardiovascular thrombosis have enabled the development of new agents with the potential to further reduce mortality and morbidity. This article reviews the role of platelets in haemostasis and cardiovascular thrombosis, and discusses the benefits and limitations of current and investigational antiplatelet agents in the treatment of cardiovascular disease.

引用

页码：154 / 169

页数：16

共 153 条

[1]

Agah R, 2007, PLATELETS, 2ND EDITION, P1145, DOI 10.1016/B978-012369367-9/50824-7

[2] In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time [J].

Ammar, T ;

Scudder, LE ;

Coller, BS .

CIRCULATION, 1997, 95 (03) :614-617

[3]

Andrews RK, 2007, PLATELETS, 2ND EDITION, P145, DOI 10.1016/B978-012369367-9/50769-2

[4] Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment [J].

Angiolillo, DJ ;

Fernandez-Ortiz, A ;

Bernardo, E ;

Ramírez, C ;

Sabaté, M ;

Jimenez-Quevedo, P ;

Hernández, R ;

Moreno, R ;

Escaned, J ;

Alfonso, F ;

Bañuelos, C ;

Costa, MA ;

Bass, TA ;

Macaya, C .

DIABETES, 2005, 54 (08) :2430-2435

[5] High clopidogrel loading dose during coronary stenting:: effects on drug response and interindividual variability [J].

Angiolillo, DJ ;

Fernández-Ortiz, A ;

Bernardo, E ;

Ramírez, C ;

Sabaté, M ;

Bañuelos, C ;

Hernández-Antolín, R ;

Escaned, J ;

Moreno, R ;

Alfonso, F ;

Macaya, C .

EUROPEAN HEART JOURNAL, 2004, 25 (21) :1903-1910

[6] Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting [J].

Angiolillo, DJ ;

Fernandez-Ortiz, A ;

Bernardo, E ;

Ramírez, C ;

Barrera-Ramirez, C ;

Sabaté, M ;

Hernández, R ;

Moreno, R ;

Escaned, J ;

Alfonso, F ;

Bañuelos, C ;

Costa, MA ;

Bass, TA ;

Macaya, C .

THROMBOSIS RESEARCH, 2005, 115 (1-2) :101-108

[7] A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study [J].

Angiolillo, Dominick J. ;

Capranzano, Piera ;

Goto, Shinya ;

Aslam, Mohammed ;

Desai, Bhaloo ;

Charlton, Ronald K. ;

Suzuki, Yoshie ;

Box, Lyndon C. ;

Shoemaker, Steven B. ;

Zenni, Martin M. ;

Guzman, Luis A. ;

Bass, Theodore A. .

EUROPEAN HEART JOURNAL, 2008, 29 (18) :2202-2211

[8] Variability in individual responsiveness to clopidogrel - Clinical implications, management, and future perspectives [J].

Angiolillo, Dominick J. ;

Fernandez-Ortiz, Antonio ;

Bernardo, Esther ;

Alfonso, Fernando ;

Macaya, Carlos ;

Bass, Theodore A. ;

Costa, Marco A. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (14) :1505-1516

[9] A snake venom metalloproteinase, kistomin, cleaves platelet glycoprotein VI and impairs platelet functions [J].

不详 .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (09) :1578-1585

[10]

Bahou WF, 2007, PLATELETS, 2ND EDITION, P179, DOI 10.1016/B978-012369367-9/50771-0

← 1 2 3 4 5 6 7 8 9 10 →